Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Silk · SciRah

Researcher profile · Semantic Scholar

A. Silk

Share profile

A. Silk — researcher profile on SciRah

h-index: 31
Works: 121
Citations: 5,168

Most-cited papers

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov, A. Diab, K. Abdallah, C. O. Iii Bingham +18 more
2017Journal of Immunotherapy for Cancer1,809 citations Open access
Semantic Scholar
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
H. Rehman, A. Silk, M. Kane, H. Kaufman
2016Journal of Immunotherapy for Cancer314 citations Open access
Semantic Scholar
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers
M. Palmeri, J. Mehnert, A. Silk, S. Jabbour +14 more
2021ESMO Open302 citations Open access
Semantic Scholar
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer.
A. Panda, J. Mehnert, K. Hirshfield, G. Riedlinger +18 more
2018Journal of the National Cancer Institute191 citations Open access
Semantic Scholar
Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer
Jenna H. Newman, C. B. Chesson, Nora L Herzog, P. Bommareddy +44 more
2019Proceedings of the National Academy of Sciences of the United States of America174 citations Open access
Semantic Scholar
PHASE I TRIAL OF ALT-803, A NOVEL RECOMBINANT INTERLEUKIN-15 COMPLEX, IN PATIENTS WITH ADVANCED SOLID TUMORS
K. Margolin, C. Morishima, V. Velcheti, Jeffrey S. Miller +13 more
2018Clinical Cancer Research158 citations Open access
Semantic Scholar
Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies
Sachin R. Jhawar, Aditya Thandoni, P. Bommareddy, S. Hassan +5 more
2017Frontiers in Oncology154 citations Open access
Semantic Scholar
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
E. Buchbinder, J. Dutcher, G. Daniels, B. Curti +11 more
2019Journal of Immunotherapy for Cancer141 citations Open access
Semantic Scholar
First-in-human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors
M. Stein, J. Bertino, H. Kaufman, T. Mayer +23 more
2017Clinical Cancer Research136 citations Open access
Semantic Scholar
Clinical characterization of colitis arising from anti-PD-1 based therapy
Daniel Y. Wang, M. Mooradian, Daewon Kim, Neil J. Shah +21 more
2018Oncoimmunology64 citations Open access
Semantic Scholar
Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration
M. Stein, J. Malhotra, R. Tarapore, U. Malhotra +30 more
2019Journal of Immunotherapy for Cancer63 citations Open access
Semantic Scholar
Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors
A. Panda, A. Betigeri, K. Subramanian, J. Ross +13 more
2017JCO Precision Oncology62 citations Open access
Semantic Scholar
BAMM (BRAF Autophagy and MEK inhibition in Melanoma): A phase I/II trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600-mutant melanoma
J. Mehnert, T. Mitchell, Alexander C. Huang, T. Aleman +18 more
2022Clinical Cancer Research58 citations Open access
Semantic Scholar
Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)
G. Hanna, E. Ruiz, N. Leboeuf, M. Thakuria +3 more
2020British Journal of Cancer55 citations Open access
Semantic Scholar
Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer
Shang-Jui Wang, K. Khullar, Sinae Kim, N. Yegya-Raman +8 more
2020Journal for ImmunoTherapy of Cancer55 citations Open access
Semantic Scholar
Immunologic Characteristics of Nonmelanoma Skin Cancers: Implications for Immunotherapy.
E. Hall, Elena Fernández‐López, A. Silk, R. Dummer +1 more
2020American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting54 citations Open access
Semantic Scholar
Intratumoral Approaches for the Treatment of Melanoma
P. Bommareddy, A. Silk, H. Kaufman
2017Cancer Journal51 citations
Semantic Scholar
Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series
J. LoPiccolo, M. Schollenberger, S. Dakhil, S. Rosner +5 more
2019Journal of Immunotherapy for Cancer50 citations Open access
Semantic Scholar
A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma
J. Mehnert, A. Silk, Jonathan H. Lee, L. Dudek +10 more
2018Pigment Cell & Melanoma Research48 citations Open access
Semantic Scholar
Optimal timing of PD-1 blockade in combination with oncolytic virus therapy.
Hong-My Nguyen, P. Bommareddy, A. Silk, Dipongkor Saha
2021Seminars in Cancer Biology46 citations Open access
Semantic Scholar
A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study
A. Silk, S. O'Day, H. Kaufman, J. Bryan +18 more
2022Cancer Immunology and Immunotherapy45 citations Open access
Semantic Scholar
Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer
Sachin R. Jhawar, Shang-Jui Wang, Aditya Thandoni, P. Bommareddy +18 more
2023Journal for ImmunoTherapy of Cancer38 citations Open access
Semantic Scholar
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
A. Silk, C. Barker, S. Bhatia, Kathryn Bollin +17 more
2022Journal for ImmunoTherapy of Cancer36 citations Open access
Semantic Scholar
An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions
Cecilia A. Larocca, N. Leboeuf, A. Silk, H. Kaufman
2020American Journal of Clinical Dermatology35 citations
Semantic Scholar
Interferon Lambda: Toward a Dual Role in Cancer
A. Lasfar, A. Zloza, A. Silk, Leonard Y. Lee +1 more
2019Journal of Interferon and Cytokine Research35 citations Open access
Semantic Scholar
Cytokine Therapy.
A. Silk, K. Margolin
2019Hematology/Oncology Clinics of North America33 citations
Semantic Scholar
Abstract CT026: Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemicpembrolizumab inadvanced melanoma patients: Interim results of the CAPRA clinical trial
A. Silk, H. Kaufman, N. Gabrail, J. Mehnert +7 more
201731 citations
Semantic Scholar
A Retrospective Study of Ipilimumab Plus Nivolumab in Anti-PD-L1/PD-1 Refractory Merkel Cell Carcinoma
Sophia Z. Shalhout, Kevin S. Emerick, Howard Kaufman, A. Silk +2 more
2022Journal of immunotherapy27 citations
Semantic Scholar
Impact of corticosteroids on allograft protection in renal transplant patients receiving anti‑PD‑1 immunotherapy
M. Danesh, P. Mulvaney, N. Murakami, L. Riella +3 more
2020Cancer Immunology and Immunotherapy22 citations Open access
Semantic Scholar
A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors
A. Silk, B. Saraiya, R. Groisberg, N. Chan +12 more
2022European Journal of Medical Research16 citations Open access
Semantic Scholar
Cost and Utilization of Immunotherapy and Targeted Therapy for Melanoma: Cross-Sectional Analysis in the Medicare Population, 2013 and 2015.
K. Seiger, C. Schmults, A. Silk, E. Ruiz
2020Journal of American Academy of Dermatology16 citations Open access
Semantic Scholar
High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma
A. Silk, H. Kaufman, B. Curti, J. Mehnert +11 more
2020Frontiers in Oncology14 citations Open access
Semantic Scholar
Characterization of clinical outcomes after shorter course hypofractionated and standard-course radiotherapy for stage I-III curatively-treated Merkel cell carcinoma.
Kevin X. Liu, M. Milligan, J. Schoenfeld, R. Tishler +9 more
2022Radiotherapy and Oncology11 citations Open access
Semantic Scholar
Predictors of immunotherapy benefit in Merkel cell carcinoma
A. Kacew, Harita Dharaneeswaran, G. Starrett, M. Thakuria +4 more
2020OncoTarget11 citations Open access
Semantic Scholar
A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma
A. Silk, B. Curti, J. Bryan, T. Saunders +9 more
2023Frontiers in Oncology9 citations Open access
Semantic Scholar
Cemiplimab for kidney organ transplant recipients with advanced cutaneous squamous cell carcinoma: CONTRAC-1.
G. Hanna, Harita Dharaneeswaran, A. Giobbie-Hurder, John J Harran +11 more
2023Journal of Clinical Oncology9 citations Open access
Semantic Scholar
Cutaneous Squamous-Cell Carcinoma after Treatment with Ruxolitinib or Belumosudil.
G. Lee, Anthony K. Guzman, S. Divito, R. Soiffer +2 more
2023New England Journal of Medicine9 citations
Semantic Scholar
A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850
K. Spencer, D. Portal, J. Aisner, M. Stein +13 more
2023OncoTarget8 citations Open access
Semantic Scholar
The Association of Radiation Dose-Fractionation and Immunotherapy Use With Overall Survival in Metastatic Melanoma Patients
Shang-Jui Wang, Sachin R. Jhawar, Z. Rivera-Núñez, A. Silk +6 more
2020Cureus8 citations Open access
Semantic Scholar
Association of Rising Cost and Use of Oral Anticancer Drugs With Medicare Part D Spending From 2013 Through 2017.
K. Seiger, A. Mostaghimi, A. Silk, C. Schmults +1 more
2019JAMA Oncology8 citations Open access
Semantic Scholar
Clinical presentation of immune-related colitis associated with PD-1 inhibitor monotherapy (MONO) and combination PD-1/CTLA-4 inhibitors (COMBO) in melanoma.
Daniel Y. Wang, D. Kim, Neil J. Shah, R. Conry +12 more
20178 citations
Semantic Scholar
A phase II study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057).
A. Silk, N. Leboeuf, G. Rabinowits, I. Puzanov +8 more
20187 citations
Semantic Scholar
A SPONTANEOUS MELANOMA MOUSE MODEL APPLICABLE FOR A LONGITUDINAL CHEMOTHERAPY AND IMMUNOTHERAPY STUDY
K. Eddy, Kajal H. Gupta, J. Pelletier, A. Isola +18 more
2023Journal of Investigative Dermatology6 citations Open access
Semantic Scholar
A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report.
B. Gastman, S. Fling, G. Ansstas, P. Funchain +12 more
2022Journal of Clinical Oncology6 citations
Semantic Scholar
Abstract 3275: Combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607
S. Hu-Lieskovan, J. Moon, J. Hyngstrom, Katie M. Campbell +16 more
2023Cancer Research5 citations
Semantic Scholar
Abstract CT139: Intratumoral oncolytic virus V937 in combination with pembrolizumab (pembro) in patients (pts) with advanced melanoma: Updated results from the phase 1b CAPRA study
A. Silk, S. O'Day, H. Kaufman, J. Bryan +17 more
2021Clinical Trials5 citations
Semantic Scholar
Peer Review #3 of "Identification of potential biomarkers and their clinical significance in gastric cancer using bioinformatics analysis methods (v0.2)"
Jie Liu, Miao Zhou, Yang-Yang Ouyang, L. Du +249 more
20205 citations Open access
Semantic Scholar
PHASE I TRIAL OF ALT-803, A NOVEL RECOMBINANT INTERLEUKIN-15 COMPLEX, IN PATIENTS WITH ADVANCED SOLID TUMORS
K. Margolin, C. Morishima, V. Velcheti, Jeffrey S. Miller +15 more
20185 citations
Semantic Scholar
Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant merkel cell carcinoma and cutaneous squamous cell carcinoma.
A. Brohl, J. Markowitz, Z. Eroglu, A. Silk +7 more
2023Journal of Clinical Oncology4 citations Open access
Semantic Scholar
Role of nivolumab maintenance therapy in advanced melanoma patients following severe immune-related adverse events from combination nivolumab and ipilimumab.
A. Maloney, A. Giobbie-Hurder, Miklos C. Fogarasi, P. Ott +7 more
2023Journal of Clinical Oncology4 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Mehnert×19
Invite
J. Mehnert — researcher profile on SciRah
H. Kaufman×15
Invite
H. Kaufman — researcher profile on SciRah
A. Zloza×14
Invite
A. Zloza — researcher profile on SciRah
P. Bommareddy×10
Invite
P. Bommareddy — researcher profile on SciRah

×9

Invite

J. Malhotra — researcher profile on SciRah

Invite

N. Leboeuf — researcher profile on SciRah

Invite

M. Kane — researcher profile on SciRah

Invite

T. Saunders — researcher profile on SciRah

Invite

C. Schmults — researcher profile on SciRah

Invite

I. Puzanov — researcher profile on SciRah

Invite

J. Aisner — researcher profile on SciRah

Invite

N. Chan — researcher profile on SciRah